Frazier Life Sciences — Full Portfolio
163 tracked investments · listed companies and verified rows first
AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders.
BiotechSan Diego, US
Robert Hoffman(Executive Officer)inMarco Londei(Executive Officer)inHamza Suria(Executive Officer, Director)inDaniel Faga(President, CEO, and Director)inChristopher Murphy(CFO)
BoardCarol Gallagher(Director)
Board seatJames N. Topper· per SEC Form D
Co-investorsBioBritNorwest Venture Partners
BiotechWestlake Village, US
Alexander Asam(Director)Ricky Sun(Director)Todd Franklin Watanabe(Executive Officer, Director)
BoardJonathan Silverstein(Director)
Board seatPatrick HeronDaniel Estes· per SEC Form D · $94.5M raise · filed Oct 2019
Co-investorsBain Capital Life SciencesRA Capital
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.
BiotechCanton, US
Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)in
BoardEran Nadav(Director)John Freund(Director)David Hirsch(Director)
Board seatPatrick Heron· per SEC Form D
Co-investorsAPERTURE Venture PartnersEcoR1 CapitalLongitude Capital
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardMichael Grey(Director)Timothy Walbert(Director)
Board seatPatrick HeronPatrick J. Heron· per SEC Form D
Co-investorsChiesi VenturesNew Enterprise Associates (NEA)RiverVest Venture PartnersNorwest Venture Partners
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)
BoardCarl Gordon(Director)Thomas Street Address 1 Woiwode(Director)Saqib Islam(Director)
Board seatPatrick Heron· per SEC Form D
Co-investorsAccess BiotechnologyFrazier Healthcare PartnersNew Leaf Venture PartnersOrbiMedVersant VenturesVivo Capital
BiotechSouth San Francisco, US
Grant E Pickering(Executive Officer, Director, Promoter)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Board seatPatrick Heron· per SEC Form D · $110M raise · filed Apr 2020
Co-investorsAbingworthMedicxiPivotal Life SciencesRed Tree Venture
Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation.
BiotechHealthtechVancouver, B.C., US
Anthony Clarke(Executive Officer)Richard Stewart(Director)Cindy Jacobs(Executive Officer, Director)Jaime Xinos(Executive Officer)inJohn Bencich(Executive Officer, Director)in
BoardBridget Martell(Director)
Co-investorsvenBio PartnersVivo Capital
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalOrbiMed
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
Co-investorsAndreessen HorowitzARCH Venture PartnersEvolution VC PartnersCity Hill VenturesColt VenturesLifeSci Venture Partners
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalGV (Google Ventures)Janus Henderson InvestorsVenrock Healthcare Capital Partners
Co-investorsBioAdvance
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalGeneral CatalystNextech InvestRA Capital+5 more
BiotechPalo Alto, US
Jaisim Shah(Executive Officer, Director)Henry Ji(Executive Officer, Director)Stephen Ma(Executive Officer, Director)David Lemus(Director)
BoardYue Alexander Wu(Director)Jay Chun(Director)
Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.
BiotechHealthtechMedical Devices
Bobak Azamian, MD, PhD(Founder)in
Co-investorsAPERTURE Venture PartnersFlying L PartnersVisionary VenturesVivo CapitalBain Capital Life SciencesRTW Investments L.P.
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.
BiotechHealthtechNew Haven, US
Thomas Sciascia(Executive Officer)Jennifer Good(Co-Founder, President & CEO)inLisa Delfini(Executive Officer)inWilliam Forbes(Executive Officer)inMichael Heffernan(Director)James Cassella(Director)
Co-investorsAPERTURE Venture PartnersNew Enterprise Associates (NEA)
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)in
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalLongitude CapitalRA Capital
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)Jay Lichter(Director)Tighe Reardon(Executive Officer)
Board seatJames Topper· per SEC Form D
Co-investorsLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPappas CapitalPfizer Venture InvestmentsOrbiMed
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases.
BiotechHealthtechCarmel, US
Richard DiMarchi(Executive Officer, Director)Peter Kent Hawryluk(Executive Officer, Director)Timothy Knickerbocker(Executive Officer, Director)inSteve Hoerter(Chairman & Chief Executive Officer)inSalomon Azoulay(Chief Medical Officer)inKaren Basbaum(Chief Business Officer)in
Board seatPatrick Heron· per SEC Form D
Co-investorsNorwest Venture PartnersIU VenturesNew Enterprise Associates (NEA)OrbiMed
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)Jon Freve(Chief Financial Officer)Bryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)inOliver Stauch(Executive Officer)inConrad Wang(Director)
Co-investorsHealthQuest CapitalvenBio PartnersRA CapitalvenBio Global Strategic
Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.
BiotechHealthtechMedical Devices
Bernard Ravina(Founder and Chief Executive Officer)Judy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)Ariel D. Jasie(Chief Business Officer and General Counsel)Tushar Misra(Chief Technical Officer)
Co-investorsAtlas VentureAccess IndustriesAccess BiotechnologyCanaan Partners
Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.
BiotechHealthtechMedical DevicesMassachusetts, US
Daniel Orlando(Chief Executive Officer)inTasos Konidaris(Executive Officer)inMartin Paz(Executive Officer)inRobert Gallotto(Executive Officer)inDaniel Tasse(Executive Officer, Director)inWilliam Scheinler(Executive Officer)in
Board seatJames N. Topper· per SEC Form D
Co-investorsHealthQuest CapitalBessemer Venture PartnersThird Rock Ventures
BiotechWaltham, US
Chris Pacheco(Director)Carlos Loya(Executive Officer, Director)
Board seatLauren Mifflin· per SEC Form D · $1.2M raise · filed Mar 2022
BiotechNewton, US
Alexey Margolin(Executive Officer, Director)Louis Brenner(Executive Officer)
BoardAxel Bolte(Director)James Topper(Director)Robert Tepper(Director)inStephen Kraus(Director)
Board seatJames N. Topper· per SEC Form D · $53M raise · filed Dec 2015
Co-investorsPontifax Venture CapitalThird Rock Ventures
South San Francisco, US
Board seatJames TopperJames W. Brush· per SEC Form D
Co-investorsOmega Funds
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Board seatJames N. Topper· per SEC Form D
Co-investorsBain Capital Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent CapitalHBM Healthcare Investments+2 more
BiotechAnn Arbor, US
Julia C. Owens(Executive Officer, Director)
BoardCarol Gallagher(Director)James Topper(Director)William Harrington(Director)Randall Whitcomb(Director)
Board seatJames N. Topper· per SEC Form D · $59.1M raise · filed Dec 2017
Co-investorsThird Rock Ventures
HealthtechPhoenix, US
ARASH ARAGHI(Executive Officer, Director)PETER SLATE(Executive Officer)BRYAN WALL(Executive Officer, Director)JASON SCALISE(Executive Officer, Director)SIMON WILLMAN(Executive Officer)DAVID JACOFSKY(Executive Officer, Director)
Board seatNathan Every· per SEC Form D · $14M raise · filed Dec 2016
BiotechCleveland, US
Arthur Brown(Executive Officer, Director)Howard Dittrich(Executive Officer)Robert Baltera, Jr.(Executive Officer, Director)Rajesh Khosla(Executive Officer, Director)
BoardKevin Lalande(Director)Jerel Davis(Director)
Board seatJames N. Topper· per SEC Form D · $31.9M raise · filed Feb 2015
Co-investorsSante Health Ventures
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Board seatPatrick Heron· per SEC Form D
Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
HealthtechLong Beach, US
Keith Arnold(Executive Officer)Rob Mahan(Executive Officer)Jim Adams(Executive Officer)Vera Appleyard(Executive Officer)DAVID SACK(Executive Officer, Director)Jennifer Gallagher(Executive Officer)
Board seatNader Naini· per SEC Form D · $14.4M raise · filed Nov 2015
Co-investorsNew Enterprise Associates (NEA)
HealthtechSan Carlos, US
Hugh Y. Rienhoff(Executive Officer, Director)Laura G. Eichorn(Executive Officer)
BoardDennis Henner(Director)Alan Sachs(Director)
Board seatPatrick Heron· per SEC Form D · $80M raise · filed Nov 2020
Co-investorsAmgen VenturesClarus VenturesFrazier Healthcare Partners
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Board seatPatrick J. Heron· per SEC Form D · $2.8M raise · filed Jul 2020
Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesSofinnova Venture Partners
BiotechHamilton
Brenton K. Ahrens(Director)James I. Healy(Director)Mark Chin(Director)Patrick J. Heron(Director)inRonald M. Hunt(Director)Shahzad Malik(Director)
Board seatPatrick Heron· per SEC Form D · $51.6M raise · filed Jan 2020
Co-investorsSofinnova Venture Partners
BiotechKing Of Prussia, US
Brian MacDonald(Executive Officer, Director)Remy Sukhija(Executive Officer)
BoardJames Topper(Director)Markus Goebel(Director)Jeffrey Bird(Director)Colin Goddard(Director)
Board seatJames N. Topper· per SEC Form D · $17.1M raise · filed Apr 2016
Bellevue, US
Scott Svenson(Executive Officer, Director, Promoter)Kelly Allison(Executive Officer)
Board seatNader Naini· per SEC Form D · $35M raise · filed Mar 2016
Menlo Park, US
David Socks(Executive Officer, Director, Promoter)
BoardYigong Ge(Director)Chen Yu(Director)Brent Ahrens(Director)
Board seatPatrick Heron· per SEC Form D · $21.3M raise · filed Jun 2015
Seattle, US
Hendrik Struik(Executive Officer, Director, Promoter)George Willett(Executive Officer, Promoter)Nader Naini(Director, Promoter)Kenneth Hanover(Director, Promoter)Joe Whitters(Director, Promoter)Ben Magnano(Director, Promoter)
Board seatNader Naini· per SEC Form D · $32.3M raise · filed Jul 2017
Belmont, US
Board seatNathan Every· per SEC Form D · $46M raise · filed Jul 2016
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)Derek Metzger(Executive Officer)
BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Rajul Jain(Director)
Board seatMaria Fardis· per SEC Form D · $89.1M raise · filed Jun 2026
Co-investorsLongitude CapitalSofinnova VenturesVida VenturesBiotechnology Value Fund
Seattle, US
Gregory R Roer(Executive Officer, Director)
Board seatNader Naini· per SEC Form D · $53M raise · filed Oct 2018
BiotechMenlo Park, US
Yigong Ge(Executive Officer, Director)Michael Savino(Executive Officer)David Socks(Director)
Board seatPatrick Heron· per SEC Form D · $10.7M raise · filed Jul 2018
Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.
AgTechBiotechDeep TechHealthtechPhiladelphia, US
Mark Hefferman(Executive Officer, Director)
BoardTadataka Yamada(Director)Cindy Cole(Director)inNancy Hong(Director)
Board seatPatrick HeronAditya Kohli· per SEC Form D
Co-investorsCompanion FundDigitalis VenturesRiverVest Venture Partners
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.
BiotechHealthtechGermantown, US
William L. Rust(Executive Officer, Director, Promoter)Carole Welsch(Executive Officer)Gi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)
Board seatJames N. Topper· per SEC Form D
Co-investorsMaryland TEDCOTEDCOJDRF T1D Fund
BiotechSan Diego, US
Cam Garner(Treasurer)Cam Gallagher(Secretary)Theodore R. Schroeder(President and Chief Executive Officer)
Board seatPatrick Heron· per SEC Form D · $45.7M raise · filed Apr 2016
BiotechGreenwood Village, US
Frank Segrave(President)Michael Beckloff(Chief Development Officer)Robert Mauro(Chief Operating Officer)Barry Barnard(Chief Financial Officer)
Board seatPatrick HeronNathan Every· per SEC Form D · $4.6M raise · filed Oct 2015
35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.
BiotechHealthtech
Ilia(CEO)Maureen(CSO)
PartnerKevin Li· led
Co-investorsvenBio PartnersJanus Henderson InvestorsVivo Capital
Co-investorsAvoro Capital Advisors
Co-investors5AM VenturesSofinnova Ventures
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtech
Co-investorsAvoro Capital Advisors
BiotechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investors5AM VenturesSamsara BioCapitalVenrock Healthcare Capital PartnersVivo Capital
Co-investorsLongitude CapitalOrbiMed
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForesite CapitalScion Life SciencesThe Innovation SpacevenBio PartnersVersant Ventures
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)
Co-investorsDroia VenturesNovartis Venture FundFrazier Healthcare PartnersRTW Investments L.P.Thuja Capital
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical Devices
Co-investorsWUTIF Capital
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
PartnerJames N. Topper· led
Co-investorsDecheng CapitalBiotechnology Value Fund
Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)
BoardCraig A. Wheeler(Director)Ted W. Love(Director)Margaret G. McGlynn(Director)
Co-investorsAvoro Capital AdvisorsCanaan PartnersNew Enterprise Associates (NEA)Prospect Venture Partners
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.
Biotech
Co-investorsOrbiMedRA CapitalFrazier
Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.
BiotechDeep Tech
Jin-Quan Yu(Founder)in
Co-investorsOrbiMed
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDamien McDevitt(President and Chief Executive Officer)in
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+3 more
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)in
Co-investorsEcoR1 CapitalIllumina VenturesNextech InvestSanofi VenturesVida VenturesGoldman Sachs
BiotechLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)Mark E. Davis(Director)Troy Wilson(Executive Officer, Director)
BoardTodd Brady(Director)Michael Martin PhD.(Director)
Co-investorsBrace Pharma
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsBrace PharmaF-Prime CapitalMoore Venture Partners
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsRA CapitalRiverVest Venture PartnersHBM Healthcare InvestmentsNovo HoldingsT. Rowe PriceWellington Management
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
Travis Murdoch, M.D.(Chief Executive Officer and Board Director)
Co-investorsAndreessen HorowitzOrbiMed
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalHEALTHCARE ROYALTY PARTNERSLongwood FundSequoia Capital
Co-investors5AM Ventures
Cancer pharmaceutical company targeting PI3 Kinase; acquired by Gilead for up to $600M.
Co-investorsLatterell Venture Partners
PartnerPatrick Heron· led
Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.
Co-investorsClavystBioJeito CapitalNorwest Venture PartnersPureos Bioventures
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
Co-investorsNovo HoldingsOmega FundsJeito CapitalNorwest Venture Partners
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).
BiotechHealthtech
Graham Heap(President, Research and Development)inEzequiel Neimark(Head of Clinical Development)inTaylor Spector(Head of Medical Affairs)inScott Stirn(Head of CMC)in
Co-investorsLongitude Capital
Co-investorsRA Capital
Co-investorsBain Capital Life Sciences
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAisling CapitalAlta PartnersAsset Management CompanyCanaan PartnersPappas CapitalSanderling Ventures
Co-investorsPfizer Venture Investments
PartnerPatrick Heron· led
Complete Pharmacy Solutions (CPS) provides pharmacy staffing and consulting services to healthcare facilities, offering 24/7 access to licensed pharmacists for medication verification and clinical consultation.
Digital HealthEnterprise SoftwareHealthtechCincinnati, US
Tom Hammons
Received FDA approval for Tracleer to treat pulmonary arterial hypertension.
PartnerJames N. Topper· led
Co-investorsAlta PartnersSofinnova Ventures
Nation's largest provider of pharmacy support services to hospitals and healthcare facilities; based in Dublin, OH.
Co-investorsFrazier Healthcare Partners
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsAN Venture PartnersLightstone VenturesLongwood Fund
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyKleiner PerkinsLongitude CapitalLumira VenturesMenlo Ventures+5 more
Deciphera is a pharmaceutical company focused on developing treatments for people living with cancer.
Biotech
Daniel Flynn(Founder)in
BiotechWaltham, US
Daniel F. Flynn, Ph.D.(Executive Officer)Oliver Rosen, M.D.(Executive Officer)inThomas Kelly(Executive Officer)Michael Taylor(Executive Officer, Director)in
BoardMichael Ross(Director)Liam Ratcliffe, M.D., Ph.D.(Director)
Co-investorsREDMILEViking Global Investors
Co-investorsRA Capital
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Co-investorsAtlas VentureEcoR1 CapitalSanofi Ventures
Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.
BiotechLeuven, BE
Co-investorsClavystBioLifeArc VenturesNovo Holdings
GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria.
BiotechHealthtech
Co-investorsAisling CapitalPatient Square Capital
BiotechEmeryville, US
Andrew Allen(Executive Officer, Director)Vassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)Shefali Agarwal(Director)Elaine Jones(Director)Naiyer A. Rizvi(Director)
Co-investorsSofinnova VenturesREDMILE
Halda provides AI agents for higher-education enrollment, including a campaign agent for personalized email outreach, a website conversion agent, and an always-on recruiter agent that responds to students via text, email, voice, and WhatsApp.
AI & Machine LearningEdTechSaaSProvo, US
Lance Hydrick(Executive Officer, Director)Dallin Palmer(Director)
BoardSid Krommenhoek(Director)in
Co-investorsAlbum VCKickstartAlbum VenturesRA Capital
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsRA CapitalTaiho Ventures, LLCVida Ventures
BiotechFintech
Co-investorsCatalys PacificLightspeed Venture PartnersRA CapitalSamsara BioCapital
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsDroia VenturesLifeArc Ventures
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Konrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
PartnerDaniel Estes· led
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesKiwoom InvestmentMuirwoods Ventures+2 more
BiotechSan Diego, US
Jonathan E. Lim, M.D.(President and Chief Executive Officer)Valerie Harding, Ph.D.(Senior Vice President, Chemistry, Manufacturing and Controls)Bernard Parker(Chief Commercial Officer)Zachary Hornby(Chief Operating Officer)Igor P. Bilinsky, Ph.D.(Executive Officer)Matt Onaitis, J.D.(Secretary and General Counsel)
PartnerPatrick Heron· led
Co-investorsF-Prime Capital
PartnerJames N. Topper· led
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Chuhan Chung(Chief Medical Officer)
Co-investors5AM VenturesFrazier Healthcare PartnersWu Capital
Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease.
BiotechHealthtech
Co-investorsForesite Capital
KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE).
BiotechHealthtech
Co-investorsLongwood FundRA Capital
Co-investorsLongwood FundSV Health Investors
Knipper provides multi-modal pharmaceutical fulfillment and dispensing services, including patient access solutions, pharmacy fulfillment, samples management, and third-party logistics for pharma companies.
Digital HealthHealthtechLogistics & Supply Chain
Co-investorsFrazier Healthcare Partners
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
BoardDan Janney(Director)
Co-investorsAvoro Capital AdvisorsAlta Partners
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value Fund+2 more
BiotechMenlo Park, US
Helen Jenkins(Chief Executive Officer)Steve Bailey(Vice President)David Johnson(Director)JIA SHENG LOO(Executive Officer, Director, Promoter)
BoardDaniel Estes, Ph.D.(President)Roger Ulrich, Ph.D.(Director)
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsLongitude CapitalOberland CapitalRiverVest Venture Partners
PartnerPatrick Heron· led
PartnerJames N. Topper· led
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.
BiotechHealthtechMedical Devices
Co-investorsBain Capital Life SciencesEQT Life SciencesLSP (Life Sciences Partners)
OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.
HealthtechMedical DevicesBridgewater, US
Co-investorsA-Rod CorpCanaan PartnersOak Investment Partners
Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
BiotechDigital HealthHealthtechMedical DevicesWayne, US
Co-investorsAgent Capital
Co-investorsRA Capital
Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.
BiotechHealthtech
Mr. Basta(CEO)
Co-investorsCatalys PacificNew Enterprise Associates (NEA)
PartnerJames N. Topper· led
PartnerPatrick Heron· led
Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Diego, US
Brett Ewald(Chief Operating Officer, Founding Member)Alyssa Levin(Chief Financial Officer)inPaul Grayson(Chief Executive Officer)
Co-investors5AM Ventures
BiotechMenlo Park, US
Brett Ewald(Executive Officer)Umesh Gangadharmath(Executive Officer)Istvan Molnar(Executive Officer)Yunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)Scott Struthers(Director)
Co-investorsDCVC (Data Collective)
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.
BiotechHealthtech
Co-investorsKleiner PerkinsSolasta VenturesThe Column GroupOrbiMed
Pharmaceutical company acquired by Biogen
Co-investorsKern Capital, LLCSofinnova Ventures
PartnerJames N. Topper· led
Rigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia.
BiotechHealthtechSouth San Francisco, US
Raul Rodriguezin
Co-investorsNew Enterprise Associates (NEA)
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.
BiotechHealthtech
Co-investorsLifeArc Ventures
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)
PartnerKevin Li· led
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalNextech InvestVida VenturesLightspeed Venture Partners+2 more
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioLongwood FundNovartis Venture FundOrbiMed+1 more
A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
PartnerDaniel Estes· led
Co-investorsCapital Midwest FundLongitude CapitalRA CapitalVivo CapitalOxford Finance LLC
Santa Monica, US
Michael Einziger(Executive Officer, Director)Edna Coryell(Executive Officer, Director)Katherine Power(Director)Jessica Goldin(Executive Officer, Director)
BoardAnn Marie Simpson(Director)
Co-investors8VCDroia VenturesNovartis Venture FundRTW Investments L.P.The Column GroupThuja Capital+1 more
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
Co-investors8VCARCH Venture PartnersJDRF T1D FundLAVLifeforce CapitalLilly Asia Ventures+1 more
SpringWorks is a biotechnology company focused on developing innovative treatments for cancer patients.
BiotechDigital HealthHealthtechMedical DevicesAustin, US
Co-investorsPfizer Venture Investments
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)Michelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)Gary Patou(Executive Officer)
Co-investorsOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent CapitalBlue Owl Capital+8 more
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)
Co-investorsMonograph Capital PartnersSanofi VenturesSV Health InvestorsDementia Discovery FundTPG
Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.
BiotechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsGV (Google Ventures)The Column Group
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBioMedPartnersFund+Nextech InvestOCCIDENT
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalNew Enterprise Associates (NEA)Sofinnova Partners+4 more
VIVUS is a pharmaceutical company developing and commercializing therapies for patients with serious medical conditions and life-limiting diseases.
BiotechHealthtechMedical Devices
John Amos(Chief Executive Officer)Santosh T. Varghese(President VIVUS Global Pharmaceutical Development & Chief Medical Officer)
Co-investorsAisling Capital
ZEMDRI (plazomicin) is an aminoglycoside antibiotic injection indicated for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible microorganisms.
BiotechHealthtech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.